S. Reischmann

发表

FHL2 expression and variants in hypertrophic cardiomyopathy

C. Hengstenberg, W. Linke, O. Müller, 2014, Basic Research in Cardiology.

The E3 ubiquitin ligase Asb2β is downregulated in a mouse model of hypertrophic cardiomyopathy and targets desmin for proteasomal degradation.

H. Schlüter, L. Carrier, T. Eschenhagen, 2015, Journal of molecular and cellular cardiology.

Ranolazine antagonizes catecholamine-induced dysfunction in isolated cardiomyocytes, but lacks long-term therapeutic effects in vivo in a mouse model of hypertrophic cardiomyopathy.

L. Maier, S. Wagner, E. Schwedhelm, 2016, Cardiovascular research.

Rescue of cardiomyopathy through U7snRNA-mediated exon skipping in Mybpc3-targeted knock-in mice

L. García, F. Weinberger, T. Voit, 2013, EMBO molecular medicine.

Comparison of the effects of a truncating and a missense MYBPC3 mutation on contractile parameters of engineered heart tissue.

L. Carrier, A. Eder, T. Eschenhagen, 2016, Journal of molecular and cellular cardiology.

Impact of ANKRD1 mutations associated with hypertrophic cardiomyopathy on contraction parameters of engineered heart tissue

Claudia Crocini, Thomas Eschenhagen, Arne Hansen, 2013, Basic Research in Cardiology.

Evidence for FHL1 as a novel disease gene for isolated hypertrophic cardiomyopathy.

Eloisa Arbustini, Christian Hengstenberg, Philippe Charron, 2012, Human molecular genetics.

I-1-deficiency negatively impacts survival in a cardiomyopathy mouse model

L. Carrier, T. Eschenhagen, F. Friedrich, 2015, International journal of cardiology. Heart & vasculature.

Proteasome inhibition slightly improves cardiac function in mice with hypertrophic cardiomyopathy

N. Hübner, H. Schulz, L. Carrier, 2014, Front. Physiol..

The E3 ubiquitin ligase Asb2β is downregulated in a mouse model of hypertrophic cardiomyopathy and targets desmin for proteasomal degradation.

H. Schlüter, L. Carrier, T. Eschenhagen, 2015, Journal of molecular and cellular cardiology.